Comparative Pharmacology
Head-to-head clinical analysis: CYCLOSET versus PERGOLIDE MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOSET versus PERGOLIDE MESYLATE.
CYCLOSET vs PERGOLIDE MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cycloset (bromocriptine mesylate) is a dopamine D2 receptor agonist. It improves glycemic control in type 2 diabetes by resetting hypothalamic circadian rhythms, thereby reducing hepatic glucose production and increasing insulin sensitivity. It also suppresses the release of very low-density lipoprotein from the liver.
Ergoline-derived dopamine D2 receptor agonist; also activates D1 and D3 receptors, and has antagonist activity at α2-adrenergic and 5-HT2B receptors.
1.6 mg to 2.4 mg administered orally once daily at bedtime. Titrate by 0.8 mg every 2 weeks based on glycemic response and tolerability.
0.05 mg orally once daily for first 2 days, then increase by 0.1-0.15 mg/day every 3 days over 12 days, then by 0.25 mg/day every 3 days until optimal response; usual therapeutic range 2-3 mg/day divided 3 times daily; maximum 5 mg/day.
None Documented
None Documented
Terminal elimination half-life is 4–6 hours in patients with normal renal function; clinically, steady-state is reached within 24 hours.
Terminal elimination half-life: 15-27 hours (mean 21 hours); clinically relevant for once-daily dosing
Renal: ~90% (30% unchanged, rest as inactive metabolites); fecal: ~10%.
Renal: 50-60% as metabolites; Fecal: 40-50%; Biliary: minor (<5%)
Category C
Category C
Dopamine Agonist / Antidiabetic
Dopamine Agonist